Hospital
Mcleod Health Cheraw
Mcleod Health Cheraw was paid $6.77M by Medicaid between Jan 2018 and Dec 2024, across 167 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 26% of everything it billed.
33Billing provider infoMCLEOD HEALTH CHERAW
CHERAW, SC 29520
CHERAW, SC 29520
33aNPI1902283740assigned 04/30/2015
33bProvider typeRural Acute Care Hospital
28Total paid$6.77M
24GClaims361,418
24DCodes billed167
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in South Carolina
Rank by total paid#2 of 5
Median peer was paid$6.15M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ERVIN, SAMUEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,392 | $847K | |
| 2019 | 50,540 | $747K | |
| 2020 | 44,586 | $639K | |
| 2021 | 57,862 | $860K | |
| 2022 | 62,152 | $1.11M | |
| 2023 | 52,305 | $1.35M | |
| 2024incomplete | 46,581 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 26% | 28,589 | 22,420 | $1.74M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 11% | 4,320 | 3,975 | $724K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.4% | 17,119 | 15,943 | $567K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.3% | 8,223 | 2,199 | $357K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.2% | 3,567 | 3,415 | $350K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.8% | 2,716 | 2,557 | $325K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.8% | 3,196 | 3,001 | $256K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.8% | 5,153 | 4,104 | $188K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 9,016 | 7,778 | $170K |
| J7030 | Infusion, normal saline solution , 1000 cc | 2.2% | 1,736 | 1,421 | $148K |
| 81001 | 2.0% | 10,565 | 9,526 | $137K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.0% | 15,537 | 14,027 | $132K |
155 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 4,395 | $120K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 1,474 | $106K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 2,073 | $106K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 5,384 | $101K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 1.3% | 1,408 | $88K |
| 81003 | 1.0% | 3,815 | $69K | |
| 81025 | 1.0% | 5,553 | $68K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 839 | $63K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,757 | $58K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,087 | $55K |
| 73610 | <1% | 817 | $51K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,005 | $51K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 363 | $46K |
| 73630 | <1% | 991 | $46K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,289 | $38K |
| 80053 | Comprehensive metabolic panel | <1% | 12,999 | $36K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,607 | $33K |
| 73030 | <1% | 780 | $33K | |
| 73130 | <1% | 503 | $32K | |
| 36416 | <1% | 3,596 | $30K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,047 | $28K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,121 | $26K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,458 | $25K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,434 | $25K |
| 87070 | <1% | 381 | $23K | |
| 99285 | Emergency room visit (most serious) | <1% | 9,009 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,369 | $21K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 202 | $18K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 26 | $16K |
| 73110 | <1% | 229 | $14K | |
| 73564 | <1% | 302 | $13K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,124 | $13K |
| 73562 | <1% | 343 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,204 | $12K |
| 97161 | <1% | 456 | $11K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,035 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,246 | $10K |
| 72100 | <1% | 301 | $10K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 138 | $9K |
| 74018 | <1% | 193 | $8K | |
| 59025 | Fetal non-stress test | <1% | 172 | $8K |
| G0378 | Hospital observation service, per hour | <1% | 2,821 | $7K |
| 96376 | <1% | 2,159 | $7K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,104 | $7K |
| 82948 | <1% | 2,208 | $7K | |
| 82803 | <1% | 742 | $6K | |
| 87040 | <1% | 3,648 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 362 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,372 | $5K |
| 87077 | <1% | 628 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 860 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 28 | $4K |
| 73502 | <1% | 171 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,467 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 827 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,449 | $2K |
| 71250 | <1% | 28 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 26 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 464 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 37 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,345 | $2K |
| 87807 | <1% | 134 | $2K | |
| 87430 | <1% | 361 | $2K | |
| 97162 | <1% | 104 | $2K | |
| 92523 | <1% | 12 | $2K | |
| 73080 | <1% | 30 | $2K | |
| 87210 | <1% | 83 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $1K |
| 84145 | <1% | 2,639 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,413 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 18 | $1K |
| 84702 | <1% | 835 | $1K | |
| 86850 | <1% | 497 | $1K | |
| 36600 | <1% | 375 | $996.74 | |
| 80076 | <1% | 1,939 | $828.49 | |
| 80061 | Lipid panel | <1% | 1,106 | $799.75 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,439 | $716.24 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 21 | $701.22 |
| 83880 | <1% | 2,836 | $672.61 | |
| 84484 | <1% | 8,904 | $615.51 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,135 | $522.97 |
| 76641 | <1% | 16 | $519.40 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,974 | $504.13 |
| 74022 | <1% | 65 | $464.56 | |
| 86900 | <1% | 807 | $437.77 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 595 | $359.15 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,098 | $259.70 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 137 | $229.50 |
| A9270 | Non-covered item or service | <1% | 2,234 | $201.46 |
| 84439 | <1% | 876 | $184.37 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 174 | $151.57 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,221 | $100.00 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 533 | $95.35 |
| 82550 | <1% | 290 | $75.31 | |
| 85610 | <1% | 3,788 | $73.86 | |
| 83735 | <1% | 9,479 | $66.23 | |
| 86140 | <1% | 250 | $33.72 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 925 | $32.82 |
| 80179 | <1% | 398 | $24.04 | |
| 80143 | <1% | 431 | $24.04 | |
| 80069 | <1% | 16 | $22.40 | |
| 83655 | <1% | 138 | $21.71 | |
| 82077 | <1% | 907 | $20.60 | |
| 83690 | <1% | 6,097 | $20.00 | |
| 85027 | <1% | 2,314 | $18.50 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,251 | $15.31 |
| 86738 | <1% | 186 | $13.24 | |
| 85730 | <1% | 3,170 | $9.19 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 185 | $7.69 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 691 | $4.09 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 196 | $4.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 929 | $0.23 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 430 | $0.00 |
| 83605 | 0% | 4,161 | $0.00 | |
| 87205 | 0% | 67 | $0.00 | |
| 86901 | 0% | 808 | $0.00 | |
| 85379 | 0% | 630 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,121 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 596 | $0.00 |
| J3490 | Unclassified drugs | 0% | 1,315 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 75 | $0.00 |
| 85651 | 0% | 60 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,151 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 245 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 19 | $0.00 |
| 84703 | 0% | 174 | $0.00 | |
| 70498 | 0% | 17 | $0.00 | |
| 70496 | 0% | 17 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 125 | $0.00 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 27 | $0.00 |
| 94760 | 0% | 137 | $0.00 | |
| 80320 | 0% | 140 | $0.00 | |
| 97165 | 0% | 46 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 60 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 40 | $0.00 |
| 87147 | 0% | 33 | $0.00 | |
| 80329 | 0% | 16 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 34 | $0.00 |
| 87081 | 0% | 14 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 608 | $0.00 |
| 87186 | 0% | 943 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 68 | $0.00 |
| 90715 | 0% | 99 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 110 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 231 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 159 | $0.00 |
| 84100 | 0% | 557 | $0.00 | |
| 83525 | 0% | 270 | $0.00 | |
| 82565 | 0% | 42 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 110 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 118 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 170 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 54 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 31 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialERVIN, SAMUEL (SR VICE PRESIDENT & CFO)
Parent organizationMCLEOD HEALTH
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.